What's Going On With Eli Lilly Shares Friday?
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.
Eli Lilly and Co. (紐交所:LLY) 股票在週五下午出現增加的活躍度。以下是你需要了解的內容。
What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lilly with a price target of $1023. Despite this bullish outlook, options trading data from Benzinga shows a mixed sentiment among high-rolling investors, with 50% bearish and 41% bullish trades spotted. Significant options activity includes 11 call options totaling $569,034 and one put option amounting to $50,300.
何時發生：大摩資源lof維持對禮來公司的超配評級，目標價爲1023美元。儘管持看漲看跌期權的高額投資者中意見不一，Benzinga的期權交易數據顯示，50%看淡，41%看好。重要的期權交易活動包括11個看漲期權，總價值569,034美元以及一個看跌期權，總價值50,300美元。
Key Developments: Eli Lilly is making strides in the pharmaceutical sector with its GLP-1 treatments like Mounjaro and Zepbound, which have shown promising results in reducing obesity-related cancer risks. A recent study in JAMA Network highlighted the reduced risk of ten types of obesity-related cancers for patients using GLP-1 treatments compared to those on insulin or other diabetes medications.
重要進展：禮來公司在藥品板塊取得進展，其Mounjaro和Zepbound等GLP-1治療藥物已經顯示出降低肥胖相關癌症風險的有希望結果。JAMA Network最近的一項研究強調，使用GLP-1治療藥物的患者相比於使用胰島素或其他糖尿病藥物的患者，患10種肥胖相關癌症的風險降低了。
Additionally, Eli Lilly's SURMOUNT-OSA phase 3 trials for tirzepatide demonstrated a significant reduction in the apnea-hypopnea index, showcasing potential benefits for treating obstructive sleep apnea.
另外，禮來公司的tirzepatide的SURMOUNt-OSA 3期試驗證明減輕了睡眠呼吸暫停低通氣指數，展示了治療阻塞性睡眠呼吸暫停的潛在益處。
Analysts' Opinions: In the past month, several analysts have weighed in on Eli Lilly. B of A Securities maintained a Buy rating with a $1000 price target, while Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885. BMO Capital also maintained an Outperform rating with a $1001 price target.
分析師的意見：在過去的一個月裏，有幾位分析師發表了對禮來公司的看法。B of A Securities維持買入評級，目標價爲1000美元，而Cantor Fitzgerald的評級則下調爲超配，目標價爲885美元。BMO Capital還維持跑贏市場的評級，目標價爲1001美元。
LLY Price Action: Eli Lilly shares were up by 1.91% at $915.23 according to Benzinga Pro.
LLY股價表現：根據Benzinga Pro，禮來公司的股價上漲了1.91%，報915.23美元。
Photo by rafapress on Shutterstock.
照片來自Shutterstock的rafapress。
譯文內容由第三人軟體翻譯。